Case Report: Patient with deficiency of ADA2 presenting leukocytoclastic vasculitis and pericarditis during infliximab treatment

Diana Simão Raimundo, Ana Isabel Cordeiro, João Parente Freixo, Marta Valente Pinto, Conceição Neves, João Farela Neves

Research output: Contribution to journalArticlepeer-review

40 Downloads (Pure)

Abstract

Deficiency of adenosine deaminase 2 (DADA2), first reported in 2014, is a disease with great phenotypic variability, which has been increasingly reported. Therapeutic response depends on the phenotype. We present a case of an adolescent with recurrent fever, oral aphthous ulcers, and lymphadenopathy from 8 to 12 years of age and subsequently presented with symptomatic neutropenia. After the diagnosis of DADA2, therapy with infliximab was started, but after the second dose, she developed leukocytoclastic vasculitis and showed symptoms of myopericarditis. Infliximab was switched to etanercept, with no relapses. Despite the safety of tumor necrosis factor alpha inhibitors (TNFi), paradoxical adverse effects have been increasingly reported. The differential diagnosis between disease new-onset manifestations of DADA2 and side effects of TNFi can be challenging and warrants further clarification.

Original languageEnglish
Article number1200401
JournalFrontiers in Pediatrics
Volume11
DOIs
Publication statusPublished - Jun 2023

Keywords

  • adenosine deaminase 2 (ADA2)
  • anti-TNF-α
  • DADA2
  • infliximab
  • leukocytoclastic vasculitis
  • pericarditis

Fingerprint

Dive into the research topics of 'Case Report: Patient with deficiency of ADA2 presenting leukocytoclastic vasculitis and pericarditis during infliximab treatment'. Together they form a unique fingerprint.

Cite this